Skip to content
Head to head

Rapport Therapeutics vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: RAPP · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

RAPP -7.8%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
RAPPVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price23.16515.02
Change today-1.82%-1.08%
1-year return-13.7%+22.0%
Market cap$1.37B$130.58B
52-week range22.06 – 52.93412.27 – 568.67
Valuation
P/E (TTM)-7.3133.14
P/E percentile, own 5-yr range73rd99th
P/B3.516.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-2.8615.32
Net profit (TTM)$-169.54M$3.88B
Revenue (TTM)$20.00M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)--+11.8%
Gross margin--85.5%
Operating margin-838.1%33.1%
Net margin-752.4%30.7%
Free cash flow (TTM)$-121.18M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership89.7%96.8%
Insider activity (12mo)22 buy / 28 sell28 buy / 22 sell
Short interest (% of float)7.0%1.9%
Analyst consensus100% buy (14)95% buy / 5% hold (21)
Analyst price target$68 (+194%)$624 (+21%)
StockVane view
StockVane Quant RatingD (25)C (68)
Company
Employees846,400
Founded20221989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.